As a leading full-service analytical laboratory serving the pharmaceutical industry for more than 30 years, at Neopharm, we are investing in the development of a new facility with state-of-the-art technology to support the growing field of biological products in the healthcare industry.
Read MoreAstraZeneca is pleased to announce it is bringing 500 highly-skilled scientific and high-tech jobs to the Greater Toronto Area (GTA) in a major expansion of its research footprint in Canada. The investment will contribute to AstraZeneca’s Research & Development Hub (R&D) in Mississauga, which focuses on leading global clinical studies in areas including breast, lung and prostate cancer, COVID-19, and chronic kidney disease. It also includes the creation of a new Alexion, AstraZeneca Rare Disease Development Hub, which focuses on rare disease research.
Read MoreToday, the Honourable François-Philippe Champagne, Minister of Innovation, Science and Industry, and the Honourable Jean-Yves Duclos, Minister of Health, announced an investment of $10 million in support of the creation of five research hubs to accelerate Canada’s vaccine and therapeutics production.
Read MoreGSK today announced an agreement with the Government of Canada for pandemic and seasonal influenza vaccines to help protect Canadian adults and children. The four-year agreement, spanning through March 2026, includes the supply of as many as 80 million doses of Arepanrix (adjuvanted pandemic influenza vaccine) in the event of an influenza pandemic(s) and a minimum of 4 million doses per year of Flulaval Tetra (seasonal influenza vaccine). Both vaccines will be supplied by GSK’s Sainte-Foy, Quebec facility. This agreement follows earlier agreements between the Government of Canada and GSK to supply both pandemic and seasonal influenza vaccines dating back to 2001.
Read MoreGE Healthcare will incorporate Imeka's neuroimaging technology into BrainWave MRI to provide additional insights into central nervous system diseases and disorders
Read MoreAbCellera (Nasdaq: ABCL) today announced an additional purchase by the U.S. government from Eli Lilly and Company (Lilly) for bamlanivimab with etesevimab for administration together.
Read MoreThis Japanese study, in combination with final data from the global Phase 2/3 study of the vaccine candidate, will be used to support an application for regulatory approval in Japan by March of 2022.
Read MoreMONTRÉAL, Aug. 10, 2021 /CNW/ - Today, the Honourable François-Philippe Champagne, Minister of Innovation, Science and Industry, announced a major milestone in Canada's strategy to rebuild the biomanufacturing and life sciences sector. The Government of Canada has established a memorandum of understanding (MOU) with leading COVID-19 vaccine developer Moderna, Inc. to build a state-of-the-art mRNA vaccine production facility in Canada.
Read More
